4D Molecular Therapeutics
FDMT | NASDAQ
$11.29
-$0.94 (-7.69%)
At close: Nov 16, 2026, 4:00 PM ET
$11.29
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-7.69%
(1D)No price chart data available for 1D timeframe.
Rating
40.8
+6.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #498/1021 (Top 49%)
Key Statistics
Market Data
Market Cap $815.72M
1D Range
11.22 12.34
52W Range
7.19 16.76
Valuation (TTM)
PE -4.05
PB 2.41
EV/EBITDA -2.66
Valuation (NTM)
Forward PE N/A
Forward PEG -0.15
Price Target $32.00
Cash Flow
FCF Yield -20.5%
SBC Adj. FCF Yield -23.4%
SBC Impact -14.5%
Margins
Gross Margin 91.5%
Operating Margin -226.1%
FCF Margin -173.9%
Growth (CAGR)
Revenue 3Y | 5Y 63.5% |
41.4%
Dil EPS 3Y | 5Y 1.9% |
0.0%
FCF 3Y | 5Y -16.1% |
-18.4%
Returns
ROA -46.7%
ROE -47.1%
ROIC -56.9%
Financial Health
Net Cash
$287.31M
Current Ratio 6.15
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's d...
Sector Healthcare
Industry Biotechnology
Employees 196
IPO Date Dec 11, 2020
Website www.4dmoleculartherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$1.08
Miss -2.86%
YoY:
-6.93% REV
$4.14M
Beat +0.28%
YoY:
+4505.55%Next Earnings
Mar 17, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$32.00
Upside
+183.44%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove FDMT